To compare the associations of individual sodium-glucose co-transporter-2 (SGLT2) inhibitors with adverse renal outcomes in patients with type 2 diabetes mellitus (T2DM).
| INTRODUCTION
The sodium-glucose co-transporter-2 (SGLT2) is located in the proximal tubule of the kidney and accounts for 90% of reabsorption of filtered glucose in the kidney.
1 SGLT2 inhibitors, highly potent in selectively inhibiting SGLT2, 2 have been approved for treating type 2 diabetes mellitus (T2DM). Unlike other glucose-lowering agents, SGLT2 inhibitors exert insulin-independent hypoglycaemia effects by selectively inhibiting renal glucose reabsorption and thereby increasing urinary glucose excretion. 3 Many clinical trials have shown that SGLT2 inhibitors have beneficial effects on glycaemic control, body weight loss and blood pressure reduction without causing hypoglycaemia. [4] [5] [6] Because of the mechanisms of action of SGLT2 inhibitors in the kidney, there is a concern that they may induce renal impairment.
Intravascular volume depletion can be caused by osmotic diuresis in patients receiving SGLT2 inhibitors. 7 Subsequently, transient hypotensive episodes secondary to volume reduction are likely to result in acute kidney injury. 8 An early and dose-dependent increase in serum creatinine or blood urea nitrogen (BUN) levels and a decrease in estimated glomerular filtration rate (eGFR) were observed after the use of SGLT2 inhibitors, especially in patients with chronic kidney disease (CKD). 9, 10 On June 14, 2016, the US Food and Drug Administration (FDA) strengthened an existing warning about the risk of acute kidney injury for canagliflozin and dapagliflozin. 11 The risk of adverse renal events was increased with the use of dapagliflozin or canagliflozin as compared with placebo 4, 12 ; however, some trials showed that early abnormal renal parameters returned toward baseline in patients receiving SGLT2 inhibitors over time. 13 Some evidence indicates that SGLT2 inhibitors might offer renoprotection in patients with T2DM. 14 Recently, 1 large randomized trial (the EMPA-REG OUT-COME trial), with up to 5 years of follow-up, showed that patients taking empagliflozin were less likely to experience acute renal failure (including acute kidney injury) than those taking placebo. 15 With regard to possible adverse effects of SGLT2 inhibitors on renal outcomes, the evidence from individual randomized trials has been inconsistent. We therefore conducted comprehensive pairwise and network meta-analyses to synthesize both direct and indirect evidence from all available randomized controlled trials (RCTs) to compare the effects of individual SGLT2 inhibitors on adverse renal outcomes in patients with T2DM. We also used cumulative metaanalysis to determine when the evidence became robust.
| METHODS
The present review was performed according to the PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of healthcare interventions. 16 
| Search strategy
The electronic databases of PubMed, Embase and the Cochrane Central Register of Controlled Trials (CENTRAL) were searched to identify eligible RCTs using relevant search terms described in Table S1 .
We identified articles published up to May 24, 2016 , without restrictions on language, year of publication or publication status. An additional manual search of the references of included trials, relevant meta-analyses, and ClinicalTrials.gov was carried out to identify other published and unpublished trials.
| Study selection
We included RCTs that compared SGLT2 inhibitors to placebo or other active antidiabetic treatments in adults with T2DM. We required follow-up periods of at least 12 weeks and reporting of at least 1 renalrelated adverse outcome (eg, increased creatinine or BUN levels, decreased eGFR, renal impairment or renal failure) in published articles.
In addition, trials with results presented on ClinicalTrials.gov were also 
| Statistical analysis
Pairwise and network meta-analyses with their odds ratios (ORs) and 95% confidence intervals (CIs) were performed to calculate comparative effect sizes.
For pairwise meta-analyses, ORs were calculated based on Peto's method for direct comparisons between SGLT2 inhibitors and control because of low event rates. 18 An I 2 statistic was used to evaluate heterogeneity within meta-analyses, with <25%, 25% to 75%, and >75%
indicating low, moderate, and high level of statistical heterogeneity,
respectively. In addition, several subgroup analyses were carried out to explore the source of heterogeneity: (1) type of control group (placebo vs active treatment); (2) length of trial duration (≤26 vs 26-104 vs ≥104 weeks); (3) age (<60 vs ≥60 years); (4) pre-existing cardiovascular disease (yes vs no); and (5) pre-existing CKD (yes vs no).
For indirect and mixed comparisons, a network meta-analysis with a random-effects model was used to compare interventions. The network meta-analysis was performed with STATA version 14.0 using the "mvmeta" command and programmed STATA routines. 19, 20 For a zeroevent RCT, a 0.5 zero-cell correction was applied. 21 To rank the SGLT2 inhibitors for a specified outcome, we estimated the relative ranking probabilities of each treatment using surface under the cumulative ranking curve (SUCRA) probabilities and mean ranks. For adverse renal outcomes, higher SUCRA probability and lower mean rank indicate a safer intervention. 22 The heterogeneity variance (tau) estimated by a restricted maximum likelihood method was employed to quantify between-study heterogeneity for each outcome. 23 To check for possible inconsistency, a loop inconsistency-specific approach was introduced to evaluate the difference between direct and indirect estimates for a specific comparison. 24 To check the assumption of consistency in the entire network, a design-bytreatment interaction model using the chi-squared test was applied. 25 To test the robustness of the findings, we assessed the modulating effects of different trial and participant characteristics on primary outcomes of sensitivity analyses restricted to trials involving patients without CKD, white patients, SGLT2 inhibitor combination therapy, or excluding the largest trial (EMPA-REG OUTCOME Trial), separately. In addition, a cumulative pairwise meta-analysis was performed to test the stability of our significant findings with the accumulation of data over time. 26 Finally, a comparison-adjusted funnel plot was used to assess small-study effects within a network of interventions, with symmetry around the summary effect line indicating the absence of small-study effects. 27 3 | RESULTS
| Study selection and study characteristics
Of 1874 citations retrieved through electronic search and 8 eligible
RCTs identified from ClinicalTrials.gov, finally, 58 eligible RCTs were included in this meta-analysis ( Figure 1 ). Table S2 summarized the characteristics of the 58 trials, in which a total of 38 079 patients were randomly assigned to groups receiving either SGLT2 inhibitors (canagliflozin, dapagliflozin, empagliflozin or luseogliflozin) or control treatments (placebo or other active antidiabetic medications). Sample sizes of individual trials ranged from 71 to 7020 participants, and the periods of follow-up ranged from 12 to 160 weeks. One trial provided 2 independent datasets for 2 different comparisons (empagliflozin vs metformin and empagliflozin vs sitagliptin), which we considered separately. 28 Combined data from 2 trials were presented on ClinicalTrials.gov and were included as 1 independent trial. 29, 30 Networks of eligible comparisons for the primary outcomes are provided in Figure 2 , showing predominantly pairwise comparisons of SGLT2 inhibitors with placebo and absence of pairwise comparison between any 2 SGLT2 inhibitors. More information is presented in Figure S1 . Figure 3A ). We generated hierarchies of treatment effects based on the SUCRA probabilities. Empagliflozin posed the lowest risk for composite renal events, whereas dapagliflozin conferred the highest risk among these 3 SGLT2 inhibitors. The network meta-analysis had low statistical heterogeneity (tau ≈ 0). We 
| Risk of bias within studies

| Meta-analysis
| Sensitivity and cumulative meta-analyses
The main results did not appreciably change in the sensitivity analysis after being restricted to trials involving patients without CKD, white patients and SGLT2 inhibitor combination therapy; however, the significantly protective effect of empagliflozin against acute renal impairment/failure seemed to be largely driven by the largest trial (EMPA-REG OUTCOME trial). 15 In addition, a cumulative meta-analysis by publication year of trials showed that dapagliflozin was significantly associated with a higher risk of composite renal events than placebo from 2014, when a trial was published by Leiter et al. 31 (cumulative OR 1.74, 95% CI 1.21-2.50) and the effect size was robust in the following years ( Figure 4A ). Consistent with the sensitivity analysis, the cumulative meta-analysis also showed that the significantly lower risk of acute renal impairment/failure from empagliflozin vs placebo was largely driven by the EMPA-REG OUTCOME trial ( Figure 4B) . Further, the comparison-adjusted funnel plot showed no small-study effects, which indicated the absence of any overestimate or underestimate of the effect of SGLT2 inhibitors ( Figure S2 ).
| DISCUSSION
Our comprehensive meta-analysis of 58 RCTs involving 39 741 patients showed that dapagliflozin was consistently associated with a
Cumulative meta-analysis of the effects of dapagliflozin on composite renal events (A), and the effects of empagliflozin on acute impairment/failure events (B).
significantly higher risk of composite renal events than was placebo.
Conversely, empagliflozin was significantly associated with a lower risk of composite renal events and acute renal impairment/failure than placebo; however, the significance of the effect on acute renal outcomes by empagliflozin was largely driven by a single study, the EMPA-REG OUTCOME trial.
Our findings clearly show that, compared with placebo, dapagliflozin was significantly associated with an increased risk of composite renal events. Moreover, the cumulative meta-analysis showed that sufficient evidence had emerged by 2014. Some previous trials also reported that dapagliflozin was associated with an increased incidence of renal impairment or failure and creatinine increase or eGFR decrease in patients with T2DM, especially in elderly patients or those with extant renal impairment. 9, 10, 31 Evidence showed that elevated serum creatinine level or lowered eGFR returned to baseline levels more frequently in patients treated with dapagliflozin than with a comparator after a few months of therapy or when therapy was discontinued. [32] [33] [34] [35] These findings indicated that abnormal changes in eGFR or creatinine during dapagliflozin therapy might reflect a tem- was not associated with elevated risk of acute renal toxicity or deterioration of renal function. 34 In the results of our meta-analysis (7 events from 9391 patients) we also found no significantly increased risk of acute renal impairment/failure associated with dapagliflozin.
Some studies have shown that renal function is reduced by other SGLT2 inhibitors, suggesting a class effect. 14, 37 Canagliflozin was associated with early abnormal changes in serum creatinine, BUN levels, or eGFR. 14 Our pairwise meta-analysis also showed that canagliflozin was significantly associated with elevated risk of composite renal events, despite a non-significantly increased risk being observed in the network meta-analysis. Empagliflozin also showed a similar pattern of short-term decrease in renal function, but with a significant improvement after the discontinuation of empagliflozin 38 ; however, our meta-analysis showed that empagliflozin was associated with decreased risk of adverse renal outcomes. Furthermore, in June 2016, the FDA strengthened an existing warning about the risk of acute kidney injury for canagliflozin and dapagliflozin. 11 As there is some evidence of the harmful effects of dapagliflozin or canagliflozin on renal function, monitoring of long-term renal function is necessary for these 2 drugs in patients with T2DM, especially those with renal impairment.
It is interesting to find that only empagliflozin was significantly associated with a lower risk of both composite renal events and acute renal impairment/failure events than placebo, suggesting this drug has possible renoprotective effects in patients with T2DM. The precise mechanisms underlying the renal benefit of empagliflozin, however, are still unclear. Some evidence showed that SGLT2 inhibitors might reduce proximal tubular hypertrophy, inflammation and fibrosis, and ameliorate the hyperfiltration that accompanies hyperglycaemia. 39 SGLT2 inhibitors might reduce albuminuria, a marker of glomerular damage in patients with CKD 9, 37, 40 ; however, it is important to note that the EMPA-REG OUTCOME trial contributed substantially to the summary estimate of acute renal impairment/failure events (~95% weight of the summary estimate), and when this trial was removed from the analysis, there was no significant difference between empagliflozin and placebo. 15 The renal benefit from empagliflozin was largely driven by the EMPA-REG OUTCOME trial. Data from well-conducted RCTs and real-world settings with renal events as primary outcomes are warranted to confirm our findings.
A key issue is whether the renal benefit from empagliflozin applies to other drugs in the SGLT2 inhibitor class, but the present findings suggest that dapagliflozin and canagliflozin may have a harmful effect on renal function. The disparate effects of the various SGLT2 inhibitors on renal impairment/failure are probably attributable to availability of data on adverse renal events. Adverse renal events associated with dapagliflozin were usually reported as adverse events in peer-reviewed journals, while most data on the other 2 SGLT2 inhibitors were extracted from ClinicalTrials.gov, with renal events being considered serious adverse events. In addition, patients with chronic comorbid disease (eg, coronary heart disease) might affect renal outcomes. 41 Empagliflozin was associated with a significant reduction in risk of renal outcomes in the EMPA-REG OUT-COME trial, which included patients with T2DM at high cardiovascular risk; however, we did not find a similar trend in other (DECLARE-TIMI58; NCT01730534), will not only provide enough statistical power to determine the renal safety of SGLT2 inhibitors, but also solve the issue of whether or not the renal benefit is a class effect or a specific drug effect.
In contrast to the null finding from 1 previous published metaanalysis, 46 the present meta-analysis showed that dapagliflozin had harmful effects on renal function, while empagliflozin had renoprotective effects. Compared with that previous study, the present meta-analysis has several advantages: (1) our research question was more specific to adverse renal outcomes; (2) this is the first network meta-analysis to assess the comparative effects of SGLT2 inhibitors on adverse renal outcomes comprehensively; (3) we systematically identified eligible RCTs that presented at least 1 adverse renal outcome; additional data from Clinicaltrials.gov were also checked to identify unpublished studies; and (4) multiple sensitivity analyses and cumulative meta-analysis were performed to test the robustness of the findings.
The present study also has some limitations. First, we focused on all or acute adverse renal outcomes as reported by trials. The adverse renal events (including an increase in creatinine or BUN levels, or a decrease in eGFR) were defined by the investigators as adverse events (or a serious adverse event), which did not allow a clear separation between chronic and acute renal outcomes or identification of each outcome. Second, the majority of the trials (especially those on canagliflozin and empagliflozin) were less likely to report adverse renal outcomes in their full publications for unknown reasons, although additional data were obtained from the ClinicalTrials.gov to minimize the risk of reporting bias. Third, variation in background treatments and patient characteristics across RCTs might contribute to heterogeneity, although we found low statistical heterogeneity and no inconsistency in our network model. Finally, adverse renal outcomes for SGLT2 inhibitors other than empagliflozin and dapagliflozin remain uncertain because of a lack of sufficient RCT data.
In conclusion, there was an increased risk of harmful effects on renal function in patients taking dapagliflozin, while empagliflozin appeared to have renal protective effects. These results call for future safety monitoring of SGLT2 inhibitors in RCTs and real-world settings.
